How effective is baxdrostat for resistant hypertension?
New late‑stage trial results
A phase 3, randomized, double‑blind, placebo‑controlled trial found baxdrostat lowered 24‑hour ambulatory systolic blood pressure in people with resistant hypertension. The study enrolled patients whose blood pressure remained high despite treatment and compared the investigational aldosterone‑synthase inhibitor with placebo.
Why the results matter
- A new mechanism: Baxdrostat targets aldosterone synthesis, a pathway implicated in salt retention and elevated blood pressure. That mechanism makes it especially relevant for patients whose hypertension does not respond well to standard regimens.
- Ambulatory monitoring: The trial used 24‑hour ambulatory systolic blood pressure as the primary measure, offering a more reliable view of blood‑pressure control throughout the day than clinic readings alone.
- Clinical potential: Demonstrating a statistically significant reduction against placebo in a phase 3 setting provides evidence that this class could add a valuable option for hard‑to‑treat patients and help reduce cardiovascular risk linked to uncontrolled hypertension.
Remaining questions and next steps
- Long‑term outcomes: It is not yet known whether blood‑pressure lowering with baxdrostat will translate into fewer heart attacks, strokes or deaths—outcome trials will be needed.
- Safety profile: The trial reported findings that support further development, but broader post‑marketing data will be required to define rare adverse events and long‑term tolerability.
- Place in therapy: Regulators, guideline panels and clinicians will need to decide where aldosterone‑synthase inhibitors fit among existing options—particularly how they compare with mineralocorticoid receptor antagonists and combination therapies.
Overall, the trial adds promising evidence that targeting aldosterone synthesis can significantly reduce ambulatory systolic blood pressure in patients with resistant hypertension, but confirmatory work on outcomes and safety remains essential.